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Abstract
High-resolution image guidance for resection of residual tumor cells would enable more precise and complete
excision for more effective treatment of cancers, such as medulloblastoma, the most common pediatric brain
cancer. Numerous studies have shown that brain tumor patient outcomes correlate with the precision of resection.
To enable guided resection with molecular specificity and cellular resolution, molecular probes that effectively de-
lineate brain tumor boundaries are essential. Therefore, we developed a bioinformatics approach to analyze micro-
array datasets for the identification of transcripts that encode candidate cell surface biomarkers that are highly
enriched in medulloblastoma. The results identified 380 genes with greater than a two-fold increase in the expres-
sion in the medulloblastoma compared with that in the normal cerebellum. To enrich for targets with accessibility
for extracellular molecular probes, we further refined this list by filtering it with gene ontology to identify genes with
protein localization on, or within, the plasma membrane. To validate this meta-analysis, the top 10 candidates were
evaluated with immunohistochemistry. We identified two targets, fibrillin 2 and EphA3, which specifically stain me-
dulloblastoma. These results demonstrate a novel bioinformatics approach that successfully identified cell surface
and extracellular candidate markers enriched in medulloblastoma versus adjacent cerebellum. These two proteins are
high-value targets for the development of tumor-specific probes in medulloblastoma. This bioinformatics method has
broad utility for the identification of accessible molecular targets in a variety of cancers and will enable probe devel-
opment for guided resection.
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Introduction
Effective surgical resection of brain tumors aims to remove as much
diseased tissue as possible while sparing the critical neural tissue imme-
diately adjacent to the malignancy. Whereas some cancers have clearly
visible margins, others, such as medulloblastoma, have margins that can
be difficult to identify [1]. While preoperative magnetic resonance im-
aging (MRI) with stereotactic positioning is commonly used to guide
resection, poor contrast and loss of position registration due to intra-
operative tissue deformation limit this image guidance technique. In
addition, the few open-configuration intraoperative MRI units that
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exist have insufficient resolution, sensitivity, and contrast to delineate
tumor margins accurately. Recent advances in micro-optical technol-
ogies have enabled the development of miniaturized microscopes to
image tumor cells during surgery [2–4]. These devices have been
shown to provide high-resolution information that complements
wide-field fluorescence image-guided surgery techniques that have
been gaining popularity among neurosurgical researchers [3–6]. For
instance, Sanai et al. [4] have reported that, in low-grade gliomas,
wide-field imaging based on 5-aminolevulinic acid–induced tumor
fluorescence is unable to distinguish between tumor and normal regions
in human patients but that individual tumor cells are identified and
quantified using a real-time surgical confocal microscope. Among this
research community, there is consensus about the potential benefits
from the use of molecularly specific optical contrast agents that are
capable of highlighting tumor tissues relative to normal brain to im-
prove tumor resection while minimizing the destruction of healthy
brain tissue.
The development of molecular probes with sufficient contrast to
delineate tumor margins requires the identification of targets highly
enriched in tumor tissues compared with adjacent, normal tissue. Un-
like pharmaceutical development, where drug targets must ideally be
present specifically in diseased tissue only, optical probe targets may be
highly expressed in other tissues so long as expression in nontumor
tissues occurs far from the surgical site. Therefore, bioinformatics tech-
niques that compare gene transcript levels in tumor versus adjacent
normal tissue can be used to mine the rich data sets available from
human tumors and from animal models as a means of identifying mo-
lecular targets for optical probe development.
One attractive disease target for optical probe development is me-
dulloblastoma, the most common brain tumor in children. Medullo-
blastoma is a solid tumor whose effective resection is both key to
prolonged disease-free survival, yet its margins are difficult to visualize
[7,8]. Consequently, 20% of children who are cured of the disease
develop severe, sometimes irreversible neurologic deficits from over-
aggressive tumor resection [9,10]. Because of these risks, aggressive
resections are often avoided. Real-time and precise image guidance
is therefore necessary to allow for complete and accurate resection
of medulloblastoma.
Here we describe the use of a novel method to identify transcripts
highly enriched in medulloblastoma. Because there is no publicly
available data set containing both medulloblastoma samples and nor-
mal cerebellum samples drawn from the same patient, we com-
pared medulloblastoma studies published by the Versteeg and the
Gilbertson groups [11,12] to normal cerebellum arrays (GSE3526
and GSE13162). Because cell surface or extracellular proteins are
preferred targets for an injected or topically applied optical probe,
we selected genes coding for proteins with known localization to
the plasma membrane or extracellular space. To validate these re-
sults, we performed immunohistochemistry on human tissue micro-
arrays to determine protein expression of the top 10 candidates
coded by the transcripts, and identified two genes, fibrillin-2 and
Eph receptor A3, with the gene products of these genes have signifi-
cantly enhanced immunoreactivity in the medulloblastoma versus that
in the cerebellum. Although immunohistochemistry is not the method
to be used for image-guided resection, it is a method of target valida-
tion. These targets can be used for the development of specific probes,
either the antibodies shown here or other molecules, for use in intra-
operative image guidance over a range of scales from high-resolution
to wide-field imaging.
Materials and Methods
Meta-analysis of Medulloblastoma Gene Expression
Microarray Experiments
Gene expression microarray samples of medulloblastoma were
obtained from NCBI Gene Expression Omnibus (GEO) experiment
GSE10327 and also from the supplementary data accompanying
Thompson et al. [12], which was downloaded from the St. Jude Research
Data Web site (http://www.stjuderesearch.org/data/medulloblastoma).
Microarray samples of normal cerebellum were obtained from NCBI
GEO experiment GSE13162. The probe set annotations for micro-
array platforms were updated using AILUN [13].
Meta-analysis of genes differentially expressed between normal cere-
bellum and medulloblastoma was conducted using the Rank Products
method [14] implemented in the RankProd package for the R statistical
language (http://r-project.org). To compensate for the fact that disease
and normal control samples did not come from the same experiment,
each set of disease samples was matched with the combined set of nor-
mal samples to form a pseudomatched case versus control experiment.
Each of these parings was assigned a unique origin identifier in the
RankProd analysis to enable aggregate rank-based meta-analysis com-
pensating for per-experiment variance. False discovery rates were
estimated by the software using 1000 randomization rounds and differ-
entially expressed genes exhibiting a fold change greater than 2 in
medulloblastoma at a false discovery rate less than 5% were selected.
The remaining genes were mapped to Gene Ontology cellular compo-
nent categories using DAVID [15], and genes annotated to be localized
on the cell membrane were retained as putative surface biomarkers
for medulloblastoma.
Immunohistochemistry
Human tissue microarrays containing humanmedulloblastoma and
normal human cerebellum (GL2082 and GL1001 from US Biomax,
Inc, Rockville, MD) were removed from paraffin and rehydrated in
water. Slides were treated with 3% hydrogen peroxide to block endog-
enous peroxidase for 10 minutes. Slides were treated with 0.1 M citric
acid at 100°C for 5 minutes and then allowed to cool to room tem-
perature for 40 minutes. Slides were then washed with phosphate-
buffered saline (PBS) and then blocked with 2% bovine serum
albumin for 30 minutes. Slides were washed with PBS and incubated
with primary antibody for 2 hours at room temperature. Slides were
washed with PBS and incubated in a biotinylated goat anti-rat or rabbit
antibody at 1:500 for 30 minutes at room temperature. Slides were
washed with PBS and incubated with streptavidin-HRP at 1:1000
for 30 minutes at room temperature. Slides were washed in PBS and
treated with diaminobenzidine. Slides were washed with PBS and
counterstained with hematoxylin. Slides were washed in water, de-
hydrated, cleared, and mounted in permanent mounting media.
Primary antibodies were rabbit anti-Eph Receptor A3 (PAB3005;
Abnova, Cambridge, MA), rabbit anti-Fibrillin (HPA012853; Sigma-
Aldrich, Seelze, Germany) and rat monoclonal anti–Laminin beta
1 antibody (Abcam, Cambridge, MA), anti–Frizzled-2 (181-461-
10749; GenWay, San Diego, CA), mouse anti–protocadherin 8
(H00005100; Abnova), rabbit anti–transforming growth factor beta
receptor I (PAB3503; Abnova), anti–connective tissue growth factor
(PAB3503; Abnova), anti–villin 2 (MAB3822; Millipore, Billerica,
MA), anti–poliovirus receptor–related 3 (HPA011038; Sigma-Aldrich),
anti-F2R (PAB11822; Abnova). Secondary antibodies were purchased
from Jackson Immunoresearch (West Grove, PA).
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Images were acquired with a Zeiss AxioVert microscope (Zeiss,
Oberkochen, Germany) with a 60× 1.4 NA objective.
Results
To identify candidate cell surface biomarkers for medulloblastoma
and building from a previously published method [16], we developed
a meta-analysis method called Public Microarray Integration of Cases
and Control (PuMiCC) to find disparate microarray data sets for cases
and controls, integrate these using rank products, and filter the differ-
entially expressed genes based on the localization of their coded proteins
within the cell. For cases of medulloblastoma, we used GSE10327 from
NCBI GEO (62 samples) and a medulloblastoma data set obtained
from St. Jude Hospital (40 samples) for a total of 102 human medullo-
blastoma microarray samples. Normal human cerebellum arrays were
derived from GSE3526 (10 samples) and GSE13162 (6 samples).
The results identified 380 genes that exhibited a greater-than-two-
fold change in expression in the medulloblastoma relative to the nor-
mal cerebellum at a false-positive rate less than 0.05. This list was then
filtered using Gene Ontology cellular component annotations to de-
rive a list of 95 genes known to be located on or within the cell mem-
brane. The top 30 candidate medulloblastoma cell surface markers are
shown in Table 1.
Ten candidate biomarkers were selected for validation by immu-
nohistochemistry (Table 2). We focused on candidate genes coding
for proteins with known localization in the outer leaflet of the plasma
membrane or in the extracellular space. Genes that had commercially
available antibodies reactive against human antigen were selected for
immunohistochemistry analysis. These antibodies were used to label
commercially available human tissue microarrays (US Biomax, Inc)
containing biopsies from 10 cases of medulloblastoma, 10 cases of nor-
mal cerebellum, and 80 cases of other brain disorders. Staining intensity
was scored on a 0 to 3+ scale. Of the 10 candidate biomarkers, fibrillin
2 was deeply stained (3+) in 4 of 10 medulloblastoma cases and EphA3
Table 1. Top 30 Most Enriched Transcripts in Medulloblastoma Verse Cerebellum.
Gene Name Symbol Fold Change
(Medulloblastoma)
Actin-like 6A ACTL6A 3.9
Centromere protein F, 350/400KA (mitosin) CENPF 3.6
Laminin, beta 1 LAMB1 3.3
CDC42 effector protein (rho GTPase binding) 3 CDC42EP3 3.2
Transmembrane protein 45A TMEM45A 3.1
Protocadherin 8 PCDH8 3.1
GTP binding protein overexpressed in
skeletal muscle
GEM 3.0
Connective tissue growth factor CTGF 3.0
Calmegin CLGN 2.9
Down syndrome critical region gene 2 PSMG1 2.9
DNAJ (HSP40) homolog, subfamily C,
member 10
DNAJC10 2.7
Villin 2 (ezrin) EZR 2.7
Solute carrier family 25, member 13 (citrin) SLC25A13 2.7
Transmembrane protein 123 TMEM123 2.7
Nucleoporin 37 kDa NUP37 2.7
Thymopoietin TMPO 2.7
SEC22 vesicle trafficking protein-LIKE 2
(Saccharomyces cerevisiae)
SEC22A 2.7
v-HA-ras Harvey rat sarcoma viral oncogene homolog NRAS 2.7
Coagulation factor II (thrombin) receptor F2R 2.6
Mitochondrial carrier family protein SLC25A40 2.6
Fat tumor suppressor homolog 4 (Drosophila) FAT4 2.6
Fibrillin 2 (congenital contractural arachnodactyly) FBN2 2.6
Frizzled homolog 2 (Drosophila) FZD2 2.6
Eph receptor A3 EPHA3 2.6
Transforming growth factor, beta receptor i TGFBR1 2.5
Kiaa1479 protein (sema6D) SEMA6D 2.5
Proline-serine-threonine phosphatase interacting
protein 2
PSTPIP2 2.5
Trophoblast glycoprotein TPBG 2.5
Poliovirus receptor–related 3 PVRL3 2.4
Solute carrier organic anion transporter
family, member 2A1
SLCO2A1 2.4
Chromosome 14 open reading frame 109 C14orf109 2.4
Zinc finger protein 643 ZNF643 2.4
Table 2. Candidate Biomarkers Selected for Immunohistochemistry Validation.
Gene Name Fold Change
(Medulloblastoma)
LAMB1 Laminin, beta 1 9.68
PCDH8 Protocadherin 8 8.59
CTGF Connective tissue growth factor 7.95
EZR Villin 2 (ezrin) 6.71
F2R Coagulation factor II (thrombin) receptor 6.03
FBN2 Fibrillin 2 5.93
FZD2 Frizzled homolog 2 (Drosophila) 5.90
EPHA3 Eph receptor A3 5.85
TGFBR1 Transforming growth factor, beta receptor I 5.71
PVRL3 Poliovirus receptor–related 3 5.41
Figure 1. Medulloblastoma but not cerebellum expresses the Eph
receptor A3 and fibrillin 2. Bright-field micrographs show immuno-
histochemical staining of the human medulloblastoma and the nor-
mal cerebellum. An anti–Eph A3 antibody (top) and an anti–fibrillin
2–antibody stained medulloblastoma (left), but not cerebellum.
Figure 2.Medulloblastoma and cerebellum stain lightly with rabbit
IgG antibody serum labeled with biotinylated goat anti–rabbit
secondary antibody. Bright-field micrographs show immuno-
histochemical staining of the human medulloblastoma and the
normal cerebellum.
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was highly stained in 3 of 10 medulloblastoma cases, whereas normal
cerebellum was nonreactive (Figure 1). Isotype controls did not stain
the medulloblastoma tissue (Figure 2).
Discussion
Taken together, we have demonstrated a novel bioinformatics ap-
proach that successfully identified cell surface and extracellular candi-
date markers enriched in medulloblastoma versus adjacent cerebellum.
Furthermore, these candidate markers were validated using immuno-
histochemistry on human tissue microarrays, revealing two genes,
fibrillin 2 and Eph receptor A3.
Fibrillins interact with integrins and heparin-sulphated proteoglycans
and likely play important roles in cell migration, adhesion, signaling,
and cell differentiation—all important processes in tumor growth and
metastasis [17]. Fibrillin 2 transcript and protein is also densely present
in rhabdomyosarcoma [18]. The related protein fibrillin 1 is present in
some glioblastomas [19], suggesting that fibrillins could be a com-
mon marker of invasive tumors. Whereas fibrillin 2 has been shown to
have a widespread distribution in the extracellular matrix of healthy
skin, lung, liver, and other tissues, it is not highly expressed in the
brain [20], making it an excellent specific target for medulloblastoma
marker development.
Eph receptors are tyrosine kinases that play a role in cell-cell inter-
action and cell migration [21]. Both Ephrin and Eph receptor over-
expression may promote tumor growth, survival, angiogenesis, and
metastasis. Mutations in Eph receptors have also been identified in
breast cancer (EPHA1, EPHA6, EPHA10) [22] and in lung cancer
(EPHA3, EPHA5, EPHA6, EPHB2, EPHB3, EPHB4) [23]. Interest-
ingly, soluble forms of Eph A receptors (EPHA2 and EPHA3) appear
to inhibit tumor angiogenesis and tumor progression [24], suggesting
that EphA3 may serve as both an optical imaging agent and a thera-
peutic target for medulloblastoma.
Because Fibrillin 2 and Eph receptor A3 have previously implicated
in tumor progression and metastasis, it is possible that optical probes
for these targets will be effective against other brain tumors as well. In
addition, as there are many tumor resection surgeries that would ben-
efit from improved surgical visualization, the techniques described
here have broad application to the identification of targets for molec-
ular probe development.
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